Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Eloxx Pharmaceuticals, Inc. amended Fifth Amendment to the Loan and Security Agreement with Hercules Capital, Inc., Hercules Capital IV, L.P., Zikani Therapeutics, Inc., Eloxx Pharmaceuticals Ltd. (effective 2024-01-09).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc., Hercules Capital IV, L.P., Zikani Therapeutics, Inc., Eloxx Pharmaceuticals Ltd.
- Effective
- 2024-01-09
Exact text from the filing
On January 9, 2024 (the “Closing Date”), Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fifth Amendment to the Loan and Security Agreement (the “Fifth Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent, and collateral agent, (ii) Hercules Capital IV, L.P., (collectively referred to as the “Lenders”), as a lender, (iii) the Company, as a borrower, (iv) Zikani Therapeutics, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, as a borrower (together with the Company, the “Borrower”), and (v) Eloxx Pharmaceuticals Ltd., an Israeli company and wholly-owned subsidiary of the Company (together with the Lenders and the Borrower, the “Parties”), which amended certain terms of the Loan and Security Agreement
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Eloxx Pharmaceuticals, Inc. entered into Purchase Agreement with SD MF 4 LLC (effective 2024-01-09).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- SD MF 4 LLC
- Effective
- 2024-01-09
Exact text from the filing
On the Closing Date, the Company also entered into a securities purchase agreement (the “Purchase Agreement”) with the Assignee (the “Purchaser”)
View on SEC.gov